CDC ACIP recommends Vaxchora as cholera vaccine for travelers
REDWOOD CITY, Calif. — The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices this voted unanimously to recommend PaxVax’s recently approved cholera vaccine Vaxchora for travelers 18 to 64 years old headed to areas of active cholera transmission.
“Cholera is an underestimated disease that is found in many popular global travel destinations in the Caribbean, Africa and Asia. Until now, U.S. travelers have not had access to a vaccine to help protect against this potentially deadly pathogen,” PaxVaxc VP clinical development and medical affairs Dr. Lisa Danzig said. “We are very proud to offer the only licensed vaccine against cholera and are encouraged by the ACIP’s recommendation which recognizes the value of Vaxchora as an important option for the protection of adults traveling to cholera-affected areas.”
Now that the ACIP has made its recommendation, the director of the CDC and the Dept. of Health and Human services have to approve it and it will then be published in the Morbidity and Mortality Weekly Report. Vaxchora was approved as the first vaccine for cholera on June 13.
Teva intros generic Entocort EC
NORTH WALES, Penn. — Teva Pharmaceuticals on Thursday announced the introduction of its generic of Entocort EC (budesonide) enteric coated 3-mg capsules. The drug is indicated to treat mild to moderate active and in remission Crohn’s disease in the ileum and/or ascending colon.
“Our customers count on Teva for a continuous supply of new generic products,” Teva SVP and general manager U.S. generics Maureen Cavanaugh said. “With the launch of budesonide capsules (enteric coated), we add another quality product to our broad line of affordable generic pharmaceuticals.”
Pfizer completes Anacor acquisition
NEW YORK — Pfizer on Friday announced that it had completed its acquisition of Anacor Pharmaceuticals. Under the terms of the acquisition, every outstanding share of Anacor’s common stock has been converted into the right to receive $99.25 in net cash.
“Now that Anacor is part of Pfizer, we can accelerate our shared commitment to help patients with inflammatory disease, an area of high unmet medical need,” Pfizer group president innovative health Albert Bourla said. “We believe that Pfizer is in a position to quickly capitalize on the benefits offered by the combination with Anacor, including the potential for a near-term U.S. product launch and subsequent commercialization of crisaborole, a differentiated asset with compelling clinical data. If approved, crisaborole has the potential to be an important first-line treatment option for patients with mild-to-moderate atopic dermatitis and the physicians who treat them.”
Pfizer said it does not expect the deal to affect its current 2016 financial guidance, and still expects it to be dilutive to earnings per share in 2017, with accretion kicking in in 2018 and increasing in the following years.
Loading Post Please Wait...